uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2025 financial results and provided significant updates on its gene therapy pipeline, primarily focusing on AMT-130 for Huntington's disease. The company announced key regulatory alignment with the FDA, securing agreement on a statistical analysis plan using a propensity score matched external control (ENROLL-HD data) for the primary efficacy analysis (3-year cUHDRS change) and CMC requirements, targeting a BLA submission in Q1 2026. Pivotal top-line 3-year data for AMT-130, critical for potential accelerated approval and a projected 2026 U.S. launch, is expected in September 2025. Additionally, uniQure highlighted encouraging early data for AMT-260 in mesial temporal lobe epilepsy, showing a 92% seizure reduction in the first patient, and anticipates initial Fabry disease data (AMT-191) in September. The company ended Q2 with $377 million in cash, projecting a runway into H2 2027, underscoring its financial stability to execute on these critical clinical and commercial milestones.

Analysis

uniQure's Q2 2025 update highlights significant progress in de-risking the regulatory and manufacturing pathway for its lead asset, AMT-130 for Huntington's disease. The company has secured critical alignment with the FDA on an accelerated approval pathway, centered on a primary efficacy analysis comparing the 3-year change in cUHDRS in high-dose patients against a propensity score-matched external control from the ENROLL-HD database. This agreement, coupled with a streamlined CMC validation process leveraging experience from HEMGENIX that requires only a single successful PPQ run, positions the company for a planned BLA submission in Q1 2026. The upcoming pivotal 3-year data readout in September 2025 is the most crucial near-term catalyst. Management expressed confidence that the pre-specified propensity-matched analysis, which aligns with FDA preference, will not yield results materially different from previously discussed methodologies. Financially, uniQure is well-capitalized with $377 million in cash and equivalents, providing a runway into the second half of 2027, which is sufficient to fund operations through the potential U.S. commercial launch of AMT-130. The pipeline is also advancing, with encouraging early data from AMT-260 in epilepsy showing a 92% seizure reduction in the first patient and initial data for AMT-191 in Fabry disease also expected in September.

Key Decisions for Investors

• Investors should focus on the pivotal 3-year data for AMT-130 in September 2025, as the magnitude of clinical benefit versus the ENROLL-HD external control will be the primary determinant of regulatory success and commercial potential.
• The explicit FDA alignment on the statistical analysis plan and CMC requirements substantially de-risks the path to a BLA submission in Q1 2026, shifting key risk from regulatory process to clinical data outcome.
• The company's cash runway into H2 2027 mitigates near-term financing risk, allowing it to fully fund the AMT-130 BLA submission and potential launch while also advancing its broader pipeline.
• Consider the potential for market expansion for AMT-130, as the newly initiated fourth cohort will evaluate patients with lower striatal volumes who were previously excluded, possibly broadening the addressable patient population post-approval.
• Monitor upcoming initial data for AMT-191 in Fabry disease in September, which provides a secondary, near-term catalyst and an indicator of the platform's broader applicability.